Brii Biosciences Limited (HKG:2137)
Hong Kong
· Delayed Price · Currency is HKD 1.550
+0.230 (17.42%)
At close: Mar 10, 2026
Brii Biosciences Employees
Brii Biosciences had 96 employees as of June 30, 2025. The number of employees decreased by 2 or -2.04% since the number was reported on December 31, 2024.
Employees
96
Change
-2
Growth
-2.04%
Revenue / Employee
328.44K HKD
Profits / Employee
-4.29M HKD
Market Cap
952.43M
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Jun 30, 2025 | 96 | -2 | -2.04% |
| Dec 31, 2024 | 98 | -30 | -23.44% |
| Dec 31, 2023 | 128 | -18 | -12.33% |
| Dec 31, 2022 | 146 | 33 | 29.20% |
| Dec 31, 2021 | 113 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| Transcenta Holding | 171 |
| Sunho Biologics | 128 |
| 3D Medicines | 183 |
| Wuhan YZY Biopharma | 106 |
| Shanghai Bio-heart Biological Technology | 70 |
| JW (Cayman) Therapeutics Co. | 292 |
| Beijing Biostar Pharmaceuticals | 131 |
| HighTide Therapeutics | 57 |
Brii Biosciences News
- 4 months ago - Brii Biosciences Announces Publication of Phase 2 ENSURE Study Results in Nature Medicine - PRNewsWire
- 7 months ago - Brii Biosciences Provides Corporate Updates and Reports 2025 Interim Financial Results - PRNewsWire
- 8 months ago - Brii Biosciences Announces Licensing Agreement with Joincare Group for Rights to BRII-693 in Greater China - PRNewsWire
- 10 months ago - Brii Bio Presents Late-Breaking Data from Its Ongoing Phase 2 ENSURE Study at EASL Congress 2025, Suggesting BRII-179's Role in Advancing Higher HBsAg Loss - PRNewsWire
- 1 year ago - Brii Bio Unveils New Data from Its Ongoing Phase 2 ENSURE Study at APASL 2025, Showcasing BRII-179's Unique Potential to Prime and Boost Higher HBsAg Loss Through Target Patient Identification - PRNewsWire
- 1 year ago - Brii Bio Announces Signing of Asset Purchase Agreements Acquiring BRII-179 IP Rights and Completed Patient Enrollment for ENRICH Study - PRNewsWire
- 1 year ago - Brii Bio Delivers First Head-to-Head Comparison of siRNA (Elebsiran) and PEG-IFNα Combination versus PEG-IFNα Alone at AASLD's The Liver Meeting® 2024, Demonstrating Higher Loss of HBV Surface Antigen by Combining with siRNA - PRNewsWire
- 1 year ago - Brii Bio Presents New Data from Its Ongoing Phase 2 Chronic Hepatitis B Trials at EASL™ Congress 2024 - PRNewsWire